CY1124322T1 - Μεθοδος για τη βελτιωση της υδατικης διαλυτοτητας των αδιαλυτων στο νερο ή των ελαφρως-υδατοδιαλυτων φαρμακων - Google Patents
Μεθοδος για τη βελτιωση της υδατικης διαλυτοτητας των αδιαλυτων στο νερο ή των ελαφρως-υδατοδιαλυτων φαρμακωνInfo
- Publication number
- CY1124322T1 CY1124322T1 CY20211100218T CY211100218T CY1124322T1 CY 1124322 T1 CY1124322 T1 CY 1124322T1 CY 20211100218 T CY20211100218 T CY 20211100218T CY 211100218 T CY211100218 T CY 211100218T CY 1124322 T1 CY1124322 T1 CY 1124322T1
- Authority
- CY
- Cyprus
- Prior art keywords
- water
- insoluble
- dissolved
- organic compound
- slightly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0291—Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Μια μέθοδος αύξησης της διαλυτότητας μιας αδιάλυτης στο νερό ή ελαφρώς υδατοδιαλυτής υδρόφοβης οργανικής ένωσης σε έναν υδατικό διαλύτη περιλαμβάνει την προσθήκη ενός συστατικού σαπωνίνης που επιλέγεται από την ομάδα που αποτελείται από εκχύλισμα εσκίνης, γλυκυρριζίνης και Quillaya saponaria στον υδατικό διαλύτη σε ποσότητα επαρκή για να προκαλέσει το σχηματισμό μικκυλίων, όπου σε ένα πρώτο στάδιο η υδρόφοβη οργανική ένωση προ-διαλύεται σε έναν οργανικό διαλύτη, οπότε σε ένα δεύτερο στάδιο ο οργανικός διαλύτης που περιλαμβάνει την προ-διαλυμένη ένωση αναμιγνύεται στον υδατικό διαλύτη, οπότε τουλάχιστον ένα μέρος της αδιάλυτης ή ελαφρώς διαλυτής υδρόφοβης οργανικής ένωσης διαλυτοποιείται και διαλύεται στον υδατικό διαλύτη, δίδοντας μια υδατική σύνθεση που έχει αυξημένη συγκέντρωση της εν λόγω οργανικής ένωσης διαλυμένη εντός αυτής. H εφεύρεση επίσης αφορά φαρμακευτικές ή καλλυντικές συνθέσεις που περιλαμβάνουν μια αδιάλυτη στο νερό ή ελαφρώς υδατοδιαλυτή οργανική ένωση διαλυμένη σε ένα υδατικό διαλύτη σε ουσιαστικά αυξημένες συγκεντρώσεις.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201514801578A | 2015-07-16 | 2015-07-16 | |
| PCT/EP2016/066999 WO2017009480A1 (en) | 2015-07-16 | 2016-07-15 | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124322T1 true CY1124322T1 (el) | 2022-07-22 |
Family
ID=56418519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100218T CY1124322T1 (el) | 2015-07-16 | 2021-03-12 | Μεθοδος για τη βελτιωση της υδατικης διαλυτοτητας των αδιαλυτων στο νερο ή των ελαφρως-υδατοδιαλυτων φαρμακων |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP3324933B1 (el) |
| JP (1) | JP6836825B2 (el) |
| KR (1) | KR102615005B1 (el) |
| CN (1) | CN107847440B (el) |
| AU (1) | AU2016293125B2 (el) |
| CA (1) | CA2992376C (el) |
| CL (1) | CL2018000032A1 (el) |
| CO (1) | CO2018001460A2 (el) |
| CY (1) | CY1124322T1 (el) |
| DK (1) | DK3324933T3 (el) |
| EA (1) | EA036233B1 (el) |
| ES (1) | ES2844581T3 (el) |
| HK (1) | HK1253027A1 (el) |
| HR (1) | HRP20210333T1 (el) |
| HU (1) | HUE053116T2 (el) |
| IL (1) | IL256882B (el) |
| LT (1) | LT3324933T (el) |
| MA (1) | MA42472B1 (el) |
| MX (1) | MX2018000286A (el) |
| MY (1) | MY196065A (el) |
| NZ (1) | NZ738592A (el) |
| PH (1) | PH12018500042A1 (el) |
| PL (1) | PL3324933T3 (el) |
| PT (1) | PT3324933T (el) |
| RS (1) | RS61561B1 (el) |
| SA (1) | SA518390688B1 (el) |
| SI (1) | SI3324933T1 (el) |
| UA (1) | UA123312C2 (el) |
| WO (1) | WO2017009480A1 (el) |
| ZA (1) | ZA201708594B (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108143713A (zh) * | 2018-01-04 | 2018-06-12 | 南方医科大学南方医院 | 一种增加羟喜树碱溶解度的方法 |
| CN110074385B (zh) * | 2019-05-21 | 2022-05-31 | 绥化市蓝源生物工程有限公司 | 一种生物碱溶解纳他霉素的生物溶剂及其应用 |
| KR20220022829A (ko) * | 2020-08-19 | 2022-02-28 | 주식회사 모든바이오 | 글리시리진 및 수용성 약물을 포함하는 나노 입자, 이를 포함하는 약제학적 조성물 및 이들의 제조 방법 |
| CN114588118B (zh) * | 2022-01-25 | 2023-05-23 | 武汉爱民制药股份有限公司 | 一种注射用七叶皂苷钠复方制剂 |
| EP4431082A1 (en) * | 2023-03-13 | 2024-09-18 | Marinomed Biotech AG | Aqueous composition comprising budesonide |
| CN117562911B (zh) * | 2023-12-07 | 2024-06-04 | 海南医学院 | 化合物tigloside在制备治疗和/或预防骨关节炎药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1119957A (en) | 1979-12-04 | 1982-03-16 | Martin Whitefield | Steroid compositions |
| US4782047A (en) | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
| US4868170A (en) | 1987-11-13 | 1989-09-19 | E. R. Squibb & Sons, Inc. | Steriod lotion formulation |
| JPH1025255A (ja) * | 1996-07-11 | 1998-01-27 | Taisho Pharmaceut Co Ltd | 溶解性の改善された難溶性薬剤 |
| FR2799369B1 (fr) | 1999-10-08 | 2001-12-21 | Oreal | Association d'escine et de sulfate de dextran et son utilisation |
| US7125564B2 (en) * | 2001-02-16 | 2006-10-24 | Lavipharm Laboratories, Inc. | Water soluble and palatable complexes |
| JP4000283B2 (ja) * | 2002-08-07 | 2007-10-31 | 丸善製薬株式会社 | 甘草油性抽出物の可溶化組成物、並びに飲料、液状調味料、化粧品及び医薬部外品 |
| US7897587B2 (en) | 2004-09-03 | 2011-03-01 | Nycomed Us Inc. | Topical dermatological formulations and use thereof |
| JP5128801B2 (ja) * | 2006-10-16 | 2013-01-23 | フロイント産業株式会社 | 高水分散性粉末とその製造方法 |
| JP6265624B2 (ja) * | 2012-05-11 | 2018-01-24 | ロート製薬株式会社 | ルリコナゾール含有外用医薬組成物 |
| WO2014163558A1 (en) * | 2013-04-01 | 2014-10-09 | Moreinx Ab | Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds |
| CN103271891B (zh) * | 2013-04-28 | 2016-01-06 | 福建南方制药股份有限公司 | 人参皂苷纳米胶束及其制备方法、应用和药物组合物 |
| CN103520081B (zh) * | 2013-09-27 | 2015-10-28 | 无限极（中国）有限公司 | 一种调节皮肤免疫力、延缓皮肤老化的外用护肤品 |
-
2016
- 2016-07-15 CN CN201680039722.5A patent/CN107847440B/zh active Active
- 2016-07-15 ES ES16739477T patent/ES2844581T3/es active Active
- 2016-07-15 NZ NZ738592A patent/NZ738592A/en unknown
- 2016-07-15 MA MA42472A patent/MA42472B1/fr unknown
- 2016-07-15 CA CA2992376A patent/CA2992376C/en active Active
- 2016-07-15 MY MYPI2017704929A patent/MY196065A/en unknown
- 2016-07-15 RS RS20210293A patent/RS61561B1/sr unknown
- 2016-07-15 MX MX2018000286A patent/MX2018000286A/es unknown
- 2016-07-15 EP EP16739477.4A patent/EP3324933B1/en active Active
- 2016-07-15 PL PL16739477T patent/PL3324933T3/pl unknown
- 2016-07-15 HU HUE16739477A patent/HUE053116T2/hu unknown
- 2016-07-15 UA UAA201712614A patent/UA123312C2/uk unknown
- 2016-07-15 LT LTEP16739477.4T patent/LT3324933T/lt unknown
- 2016-07-15 EA EA201890194A patent/EA036233B1/ru unknown
- 2016-07-15 AU AU2016293125A patent/AU2016293125B2/en active Active
- 2016-07-15 WO PCT/EP2016/066999 patent/WO2017009480A1/en active Application Filing
- 2016-07-15 SI SI201631114T patent/SI3324933T1/sl unknown
- 2016-07-15 PT PT167394774T patent/PT3324933T/pt unknown
- 2016-07-15 JP JP2017566080A patent/JP6836825B2/ja active Active
- 2016-07-15 KR KR1020187004268A patent/KR102615005B1/ko active IP Right Grant
- 2016-07-15 DK DK16739477.4T patent/DK3324933T3/da active
-
2017
- 2017-12-18 ZA ZA2017/08594A patent/ZA201708594B/en unknown
-
2018
- 2018-01-03 SA SA518390688A patent/SA518390688B1/ar unknown
- 2018-01-04 PH PH12018500042A patent/PH12018500042A1/en unknown
- 2018-01-05 CL CL2018000032A patent/CL2018000032A1/es unknown
- 2018-01-11 IL IL256882A patent/IL256882B/en unknown
- 2018-02-14 CO CONC2018/0001460A patent/CO2018001460A2/es unknown
- 2018-09-27 HK HK18112405.4A patent/HK1253027A1/zh unknown
-
2021
- 2021-02-28 HR HRP20210333TT patent/HRP20210333T1/hr unknown
- 2021-03-12 CY CY20211100218T patent/CY1124322T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124322T1 (el) | Μεθοδος για τη βελτιωση της υδατικης διαλυτοτητας των αδιαλυτων στο νερο ή των ελαφρως-υδατοδιαλυτων φαρμακων | |
| CY1122472T1 (el) | Συζευγμα-αντισωματος-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου | |
| BR112017023161A2 (pt) | composições de ácido obeticólico e métodos de uso | |
| EA201892173A1 (ru) | Фармацевтический состав палбоциклиба и способ его получения | |
| CY1121783T1 (el) | Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου | |
| BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| BR112017009651A2 (pt) | composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer. | |
| NZ709620A (en) | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid | |
| CL2018000363A1 (es) | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana. | |
| BR112018072248A2 (pt) | composições e métodos relacionados a imunógenos contra hiv-1 | |
| UY37091A (es) | Cepas fúngicas solubilizantes de fosfato | |
| FR3058059B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
| CO2019013342A2 (es) | Formulaciones de medicamentos de moleculas pequeñas resistentes a la precipitación | |
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
| BR112019007498A2 (pt) | composições farmacêuticas, método para tratar um câncer, tetróxido de diarsênio e seu uso e método para entregar uma quantidade terapeuticamente eficaz de um íon arsênio | |
| EA202090978A1 (ru) | Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции | |
| EA201691825A1 (ru) | Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта) | |
| BR112018007475A2 (pt) | ?solvente de extração e/ou solubilização, método para extrair compostos biológicos naturais, usos do solvente de extração e/ou solubilização e do extrato, e, extrato biológico natural? | |
| CL2017001077A1 (es) | Composiciones farmacéuticas que comprenden lobeglitazona para administración oral | |
| WO2018001270A1 (en) | Palbociclib prodrugs and composition thereof | |
| UA115675U (xx) | Спосіб одержання дієтичної добавки "імунан" | |
| BR112016028412A2 (pt) | composição farmacêutica, método para a preparação de uma composição farmacêutica, e kit | |
| MY173692A (en) | Method for preparing drug-loaded amphiphilic copolymer micelle and composition thereof | |
| UY37165A (es) | Uso de una composición acuosa para disolver biomoléculas a partir de una muestra de tejido |